Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by Needham & Company LLC to $95.00 in a report released on Tuesday, The Fly reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 25.20% from the company’s current price.

Several other equities research analysts have also issued reports on NBIX. Oppenheimer set a $95.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Deutsche Bank reissued a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Citigroup reissued a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, Robert W. Baird reissued a “buy” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Neurocrine Biosciences presently has an average rating of “Buy” and an average target price of $82.31.

Neurocrine Biosciences (NASDAQ NBIX) traded down $0.21 during mid-day trading on Tuesday, hitting $75.88. 1,135,600 shares of the stock traded hands, compared to its average volume of 1,125,073. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences has a twelve month low of $38.43 and a twelve month high of $83.84. The stock has a market cap of $6,930.00, a price-to-earnings ratio of -34.18 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the previous year, the company earned ($0.43) earnings per share. research analysts expect that Neurocrine Biosciences will post -1.61 EPS for the current year.

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 10,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $72.92, for a total value of $729,200.00. Following the completion of the sale, the director now owns 272,066 shares in the company, valued at approximately $19,839,052.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Darin Lippoldt sold 15,237 shares of the stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00. Following the completion of the sale, the insider now owns 28,394 shares of the company’s stock, valued at approximately $2,129,550. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,405 shares of company stock valued at $8,588,519. Insiders own 4.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. First Trust Advisors LP raised its holdings in Neurocrine Biosciences by 29.0% in the 3rd quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock valued at $47,963,000 after acquiring an additional 176,136 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Neurocrine Biosciences by 2.6% in the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after acquiring an additional 140,639 shares during the last quarter. Davidson Kempner Capital Management LP acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $3,639,000. Artisan Partners Limited Partnership acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $15,981,000. Finally, State Street Corp raised its holdings in Neurocrine Biosciences by 5.1% in the 2nd quarter. State Street Corp now owns 2,710,196 shares of the company’s stock valued at $124,666,000 after acquiring an additional 131,141 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This news story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://theolympiareport.com/2018/01/18/neurocrine-biosciences-nbix-price-target-raised-to-95-00.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

The Fly

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.